Thursday, February 21, 2013
Researchers at Roche's Genentech Inc. unit have shown
that the receptor tyrosine kinase ligand neuregulin
1 can drive resistance to chemotherapy in non-small cell lung
cancers. Although the precise mechanism is being worked out, countering
resistance by hitting neuregulin 1 or its receptors in conjunction with
conventional chemotherapy could prevent chemo resistance.1
Osherovich, L. SciBX 6(7); doi:10.1038/scibx.2013.155 Published online Feb.
1. Hegde, G.V. et al.
Sci. Transl. Med.; published online Feb. 6, 2013; doi:10.1126/scitranslmed.3004438
Contact: Erica L. Jackson, Genentech Inc., South San Francisco, Calif. e-mail:
2. Dhomen, N.S. et al.
Crit. Rev. Oncog. 17, 31-50 (2012)
3. Blackburn, E. et al.
Breast Cancer Res. Treat. 134, 53-59 (2012)
AND INSTITUTIONS MENTIONED
Genentech Inc., South San Francisco, Calif.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
University of Kent, Canterbury, U.K.